CytomX Therapeutics

CytomX Therapeutics

A biotechnology company that develops Probodies, proteolytically-activated antibodies to treat cancer.

CytomX Therapeutics is a privately funded and publicly traded biotechnology company based in the South San Francisco, California and was founded in 2008 by Fred Gluck and Patrick Daugherty. It is a clinical stage oncology-focused biopharmaceutical company pioneering in a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.

Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. CytomX's product pipeline includes cancer immunotherapies against clinically-validated targets. CX-072 and CX-188 are PD-L1 targeting Probody therapeutic. CX-2009 is an in-class Probody drug conjugate targeting CD166. All three are owned wholly by CytomX.

The company is also collaborating with other biopharmaceutical companies including AbbVie, Amgen, Bristol-Myers Squibb Company, and ImmunoGen, Inc. BMS-986249 is a CTLA-4 targeting Probody therapeutic partnered with Bristol Myers Squibb. CX-2029 is a DC71 targeting Probody drug conjugate partnered with AbbVie.

All products, except CX-188 are in various Phase 1/2 clinical trial progression. CX-2009 is currently being evaluated in its clinical trial, while CX-2009 and BMS-986249 are enrolling patients for the clinical studies.

Timeline

August 2012

CytomX Therapeutics raises a $41,000,000 series B round from Third Rock Ventures, Roche Venture Fund and Canaan Partners.

September 23, 2010

CytomX Therapeutics raises a $30,000,000 series B round from Third Rock Ventures and Roche Venture Fund.

2008

CytomX Therapeutics was founded by Patrick Daugherty.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Alison Joly

Senior VP, Program and Alliance Management

Charles S. Fuchs

Director

Danielle Olander

Senior VP, Talent and Administrative Operations

Debanjan Ray

CFO

Eric Kanowsky

Investor

Fred Gluck

Co-Founder & Director

George Holbrook

Investor

Hoyoung Huh

Chairman

Jim West

Employee

John Petote

Investor

John Scarlett

Director

Lloyd A. Rowland, Jr.

Senior VP, General Counsel, Secretary, & Chief Compliance Officer

Matthew Young

Director

Mike Panesis

Investor

Olga Vasiljeva

Employee

Patrick Daugherty

Founder

Rachel Humphrey

Chief Medical Officer

Sean A. McCarthy

President & CEO

Sridhar Viswanathan

Senior VP, Process Sciences and Manufacturing Operations

W. Michael Kavanaugh

Chief Scientific Officer & Head of Research and Non-Clinical Development

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.